Catalent (NYSE:CTLT) had its target price upped by Jefferies Financial Group from $44.00 to $50.00 in a research report report published on Tuesday, The Fly reports. They currently have a hold rating on the stock.
Several other brokerages have also recently issued reports on CTLT. UBS Group raised shares of Catalent from a neutral rating to a buy rating and boosted their price objective for the company from $43.00 to $54.00 in a research note on Tuesday. ValuEngine raised shares of Catalent from a hold rating to a buy rating in a research note on Monday. First Analysis reissued an outperform rating and set a $49.00 price objective on shares of Catalent in a research note on Tuesday, March 5th. Zacks Investment Research cut shares of Catalent from a buy rating to a hold rating in a research note on Tuesday, April 9th. Finally, TheStreet raised shares of Catalent from a c rating to a b- rating in a research note on Wednesday, February 6th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $49.57.
CTLT stock opened at $42.56 on Tuesday. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 2.43 and a beta of 1.69. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63. Catalent has a one year low of $29.23 and a one year high of $46.43.
In other news, insider Aristippos Gennadios sold 3,392 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $42.18, for a total value of $143,074.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Lance Miyamoto sold 43,619 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,326 shares of company stock valued at $2,303,676. 1.40% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Nordea Investment Management AB grew its position in shares of Catalent by 36.0% during the 3rd quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock valued at $4,997,000 after buying an additional 29,008 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Catalent by 29.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after buying an additional 1,819,020 shares during the last quarter. First Bank & Trust grew its position in shares of Catalent by 13.9% during the 4th quarter. First Bank & Trust now owns 4,600 shares of the company’s stock valued at $143,000 after buying an additional 563 shares during the last quarter. AQR Capital Management LLC grew its position in Catalent by 234.5% in the 3rd quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock worth $3,740,000 after purchasing an additional 57,562 shares during the last quarter. Finally, Blueshift Asset Management LLC bought a new position in Catalent in the 4th quarter worth about $815,000. Institutional investors and hedge funds own 99.82% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Ex-Dividend
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.